Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMAGINE 8 double-dose insulin peglispro versus insulin glargine study in type 2 diabetes
2012-005174-56Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2014
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 3 trial of insulin glargine, insulin peglispro in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Feb 2014; status: completed.
02
Drugs
insulin glargineinsulin peglispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2012-005174-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005174-56.